A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver ...
PSC occurs in 1 out of 10,000 people, who are mostly male adults between 30 and 60 years old, and it commonly develops in ...
In a randomized clinical trial, vixarelimab demonstrates dose-dependent, long-term safety and efficacy in patients with ...
A new monoclonal antibody treatment has shown promising results for a rare liver disease called primary sclerosing ...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA ...
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID ...
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an ...
More health systems across the U.S. are offering monoclonal antibody treatment as a way of fighting COVID-19 infection, but how exactly do the treatments work, and how effective are they in reducing ...
The race is on for new treatments that stand up to omicron's explosive spread. With omicron's explosive spread threatening to outpace current COVID-19 treatments, the race is on to find new options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results